HypertensionRDNP-2012-02NCT02016573
Renal Denervation for Uncontrolled Hypertension
A study testing Renal Denervation in people with Hypertension, run by Baker Heart and Diabetes Institute.
Trial summary
This is a study investigating the safety and usefulness of the Renal Denervation Procedure in reducing high blood pressure in people whose blood pressure is not adequately controlled despite already being treated with 2 blood pressure lowering drugs. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Hypertension
- What is being tested?
- Renal Denervation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Dec 2013to Apr 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- BP ≥140/90 mmHg (or ≥130/80 mmHg for patients with diabetes)
- concurrent treatment with 2 anti-hypertensive drugs
Who cannot join
- renal artery anatomy ineligible for treatment
- eGFR <15mL/min/1.73m2 (using MDRD formula)
- individual has had myocardial infarction, unstable angina or cerebrovascular accident within 6 months of screening visit
- female participants of child bearing potential must have negative pregnancy test prior to treatment
About this study
This is a study investigating the safety and usefulness of the Renal Denervation Procedure in reducing high blood pressure in people whose blood pressure is not adequately controlled despite already being treated with 2 blood pressure lowering drugs. This study is designed to compare the effects renal denervation to a usual care group.
Read the detailed description
This is a phase 4 randomised control trial of renal denervation for the treatment of uncontrolled hypertension.
Previous studies have shown that the renal denervation procedure is safe and effective in reducing blood pressure.
A total of 100 participants with uncontrolled blood pressure, treated with two blood pressure lowering medications will be recruited into the study. Patients will be assigned to one of two groups. Participants in Group 1 will be assigned to undergo the renal denervation procedure. Participants in group 2 will undergo usual care, receiving additional antihypertensive medication in an attempt to reach blood pressure targets.
The duration of this study is 36 months.
- Conditions
- Hypertension
- Being tested
- Renal Denervation
- Keywords
- renal denervation, blood pressure, cardiovascular risk, target organ damage, sympathetic activity
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Renal DenervationDevice
Also called Symplicity Renal Denervation Catheter
Renal Denervation Catheter
| Study group | Role | What they receive |
|---|---|---|
| Usual care | No intervention | participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets |
| Renal Denervation Group | Experimental | participants randomised to undergo the renal denervation procedure Receives: Device: Renal Denervation |
What is being measured
The primary outcome is the main question the study is designed to answer.
blood pressure control
percentage of patients who achieve BP target at 6 months post intervention
Measured: 6 months post procedure
Secondary outcomes (9)
number of drugs required to reach target blood pressure
number of drugs required to reach target blood pressure
Measured: baseline to 6 months
time to achieve blood pressure target
time to achieve blood pressure target
Measured: baseline to 6 months
change in sympathetic nerve activity
changes in muscle sympathetic nerve activity (MSNA), renal and whole body Noradrenaline (NA) spillover
Measured: baseline to 6 months
Change in left ventricular function
Change in left Ventricular ejection fraction, diastolic filling
Measured: baseline to 6 months
Change in Quality of Life
Change in Quality of life as assessed be relevant questionnaires
Measured: baseline to 6 months
Change in Serum Biochemistry
Plasma Renin Activity, aldosterone levels, estimated Glomerular Filtration Rate(eGFR), inflammatory markers, fasting glucose, fasting insulin, C-peptide, Homeostasis Model Assessment (HOMA) index, Lipid profile
Measured: baseline to 6 months
Change in markers of arterial stiffness
Change in markers of arterial stiffness as assessed by Augmentation Index (AI) and Pulse Wave Velocity (PWV)
Measured: baseline to 6 months
Change in left ventricular structure
Change in left ventricular mass index
Measured: baseline to 6 months
Change in Urine Biochemistry
Urinary albumin creatinine ratio (UACR), 24 hour urinary creatinine clearance, sodium
Measured: baseline to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2013 (estimated)
- Study startDec 2013 (estimated)
- Primary completionApr 2015 (estimated)
- Study completionApr 2015 (estimated)
Why it stopped: No participants enrolled into study and protocol has been superseded
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Baker Heart and Diabetes Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Markus P Schlaich, MD, Principal investigator, Baker IDI Heart & Diabetes Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02016573
- Sponsor's protocol ID
- 070/12
- Other IDs
- 1034397
- Acronym
- RDNP-2012-02
- Status last verified
- Nov 2018
- First submitted
- 16 Dec 2013
- Last updated
- 6 Nov 2018
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No: No data available
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Renal Denervation for Uncontrolled Hypertension
- ClinicalTrials.gov ID
- NCT02016573
- Acronym / sponsor ID
- RDNP-2012-02 / 070/12
- Conditions
- Hypertension
- Keywords
- renal denervation, blood pressure, cardiovascular risk, target organ damage, sympathetic activity
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: No participants enrolled into study and protocol has been superseded
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Baker Heart and Diabetes InstituteUniversity, hospital or other
- Study start
- Dec 2013 (estimated)
- Primary completion
- Apr 2015 (estimated)
- Study completion
- Apr 2015 (estimated)
- First posted
- 20 Dec 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study investigating the safety and usefulness of the Renal Denervation Procedure in reducing high blood pressure in people whose blood pressure is not adequately controlled despite already being treated with 2 blood pressure lowering drugs. This study is designed to compare the effects renal denervation to a usual care group.
Detailed description
This is a phase 4 randomised control trial of renal denervation for the treatment of uncontrolled hypertension.
Previous studies have shown that the renal denervation procedure is safe and effective in reducing blood pressure.
A total of 100 participants with uncontrolled blood pressure, treated with two blood pressure lowering medications will be recruited into the study. Patients will be assigned to one of two groups. Participants in Group 1 will be assigned to undergo the renal denervation procedure. Participants in group 2 will undergo usual care, receiving additional antihypertensive medication in an attempt to reach blood pressure targets.
The duration of this study is 36 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Usual care | No intervention | –participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets |
| Renal Denervation Group | Experimental | Device: Renal Denervationparticipants randomised to undergo the renal denervation procedure |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- BP ≥140/90 mmHg (or ≥130/80 mmHg for patients with diabetes)
- concurrent treatment with 2 anti-hypertensive drugs
Key exclusion criteria (4 listed)
- renal artery anatomy ineligible for treatment
- eGFR <15mL/min/1.73m2 (using MDRD formula)
- individual has had myocardial infarction, unstable angina or cerebrovascular accident within 6 months of screening visit
- female participants of child bearing potential must have negative pregnancy test prior to treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Renal DenervationAlso: Symplicity Renal Denervation CatheterRenal Denervation Catheter | Device | Renal Denervation Group |
Primary outcome
blood pressure control
Time frame: 6 months post procedure
percentage of patients who achieve BP target at 6 months post intervention
9 secondary outcomes
number of drugs required to reach target blood pressure
Time frame: baseline to 6 months
time to achieve blood pressure target
Time frame: baseline to 6 months
change in sympathetic nerve activity
Time frame: baseline to 6 months
Change in left ventricular function
Time frame: baseline to 6 months
Change in Quality of Life
Time frame: baseline to 6 months
Change in Serum Biochemistry
Time frame: baseline to 6 months
Change in markers of arterial stiffness
Time frame: baseline to 6 months
Change in left ventricular structure
Time frame: baseline to 6 months
Change in Urine Biochemistry
Time frame: baseline to 6 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2018.
- Individual participant dataSharing planned: No. No data available
Related trials for Hypertension
Not yet recruiting
PAUL® Glaucoma Implant Safety and Effectiveness Study
Refractory Glaucoma
RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
RecruitingObservational study
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage, Stroke
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Markus P Schlaich, MD principal investigator
Baker IDI Heart & Diabetes Institute
Questions about this trial
What is this clinical trial studying?
A study testing Renal Denervation in people with Hypertension, run by Baker Heart and Diabetes Institute.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 6 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
blood pressure control (time frame: 6 months post procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2018.